Key Insights• The Japanese radiotherapy market operates within a sophisticated universal healthcare system, with cancer remaining a leading cause of mortality and radiotherapy playing a central role in curative and palliative treatment. The Japanese Society for Radiation Oncology's structure surveys have documented an installed base of 936 linear accelerators (2015 survey), with IMRT functions available in 628 units and 3D conformal radiotherapy in 867 units .• External Beam Radiotherapy (EBRT) constitutes the largest therapy segment, supported by extensive LINAC infrastructure and widespread adoption of advanced techniques including IMRT and IGRT. The Japanese government's Fourth Cancer Control Basic Plan prioritises both the equalisation and concentration of high-cost radiotherapy equipment, balancing accessibility with operational efficiency .• Radiotherapy systems and equipment represent the largest offering segment, with the market characterised by significant domestic manufacturing capability. Sumitomo Heavy Industries has delivered proton therapy systems since 1997 and continues to develop cyclotron-based solutions , while Hitachi High-Tech launched the domestically produced OXRAY image-guided X-ray therapy system in July 2023, developed in partnership with Kyoto University to preserve domestic technology capabilities .• Hospitals and integrated cancer centres are the largest end-user segment, operating within the public health system. However, workforce constraints persist the proportion of designated cancer care hospitals with at least one full-time specialised radiotherapy nurse has declined to below 50% and IMRT remains unavailable in approximately 20% of these hospitals .• Regulatory oversight is provided by the Ministry of Health, Labour and Welfare under the Medical Care Act and the Fourth Cancer Control Basic Plan. The government is actively supporting advanced radiotherapy research, with the Japan Agency for Medical Research and Development evaluating MR-Linac efficacy and safety to inform appropriate provision of high-precision radiotherapy .Market Outlook• According to the research report, "Japan Radiotherapy Market Overview, 2031," published by Actual Market Research, the Japan Radiotherapy market is anticipated to add to more than USD 370 Million by 2026–31. This growth reflects sustained government investment in cancer care infrastructure, technology modernisation, and increasing cancer burden across the aging population.• The market is expected to benefit from continued government support for radiotherapy modernisation.

The Ministry of Health, Labour and Welfare is actively promoting the equalisation and concentration of high-cost medical equipment including radiotherapy devices under the Fourth Cancer Control Basic Plan, with a view to 2040 healthcare delivery needs . Demand for radiotherapy is projected to increase by 38% between 2025 and 2040, compared to an 11% decline in surgical procedures, underscoring the strategic importance of radiation oncology .• Technology adoption is accelerating through domestic manufacturing innovation. Hitachi High-Tech's OXRAY system, launched in July 2023, represents a significant advancement in domestically produced image-guided X-ray therapy, featuring O-ring gantry design, dual kV imaging, and motion-tracking irradiation capabilities . The system supports adaptive radiotherapy, which is expected to become mainstream in radiation oncology. The Japanese government is also evaluating MR-Linac through AMED research, with plans to establish appropriate provision systems for advanced radiotherapy .• The market is also influenced by workforce and infrastructure challenges. While LINAC infrastructure has improved significantly with 936 units documented in the 2015 survey personnel shortages persist .

The proportion of designated cancer hospitals with specialised radiotherapy nurses has declined below 50%, and approximately 20% of cancer care hospitals still lack IMRT capability, indicating ongoing investment requirements .• Long-term growth is supported by demographic trends and sustained policy commitment. The Ministry of Health's demand projections indicate that radiotherapy will be one of the few growing treatment modalities through 2040, driving continued infrastructure and workforce investment .Market DynamicsDriver: Sustained Government Investment and Cancer Control PolicyThe primary driver of the Japanese radiotherapy market is sustained government investment through the national cancer control framework. The Fourth Cancer Control Basic Plan provides the strategic foundation for radiotherapy infrastructure development, with the Ministry of Health, Labour and Welfare actively promoting both equalisation (ensuring geographic access) and concentration (maintaining operational efficiency) of high-cost radiotherapy equipment . Demand projections indicate that radiotherapy demand will increase by 38% between 2025 and 2040, driving continued investment . The government is also supporting advanced technology research, with AMED evaluating MR-Linac efficacy and safety to inform future policy and reimbursement frameworks . This sustained policy commitment ensures consistent demand for radiotherapy equipment, software, and maintenance services.Challenge: Workforce Shortages and Infrastructure ConcentrationA significant challenge facing the Japanese radiotherapy market is the persistent shortage of specialised personnel and the need to balance infrastructure concentration with accessibility.

While LINAC infrastructure has improved 936 units documented in the 2015 survey with IMRT available in 628 units workforce constraints remain critical . The proportion of designated cancer care hospitals with at least one full-time specialised radiotherapy nurse has declined to below 50%, and approximately 20% of these hospitals still lack IMRT capability . The Japanese Society for Radiation Oncology has documented shortages of radiation oncologists and medical physicists . The government's policy of concentrating high-cost equipment to improve efficiency while ensuring that patients do not become "lost" in the system requires careful implementation to avoid creating access barriers . Additionally, equipment costs are rising significantly, prompting consideration of patient concentration to ensure efficient equipment operation .Trend: Domestic Manufacturing Innovation and Technology AdvancementA major trend shaping the Japanese radiotherapy market is the advancement of domestic manufacturing and technology innovation. Hitachi High-Tech's OXRAY system, launched in July 2023, represents a significant domestically produced image-guided X-ray therapy system developed in partnership with Kyoto University .

The system features an O-ring gantry, dual kV imaging, motion-tracking irradiation, and support for adaptive radiotherapy expected to become mainstream in radiation oncology . The development was driven by a determination to preserve domestic technology capability after an overseas manufacturer halted development of a preceding system. Sumitomo Heavy Industries has supplied more than 250 PET cyclotron systems worldwide and continues to develop proton therapy and BNCT systems . The Japanese government is also evaluating MR-Linac through AMED research, indicating support for next-generation technology adoption . This trend toward domestic innovation supports technology leadership and reduces dependency on international suppliers.Policies• The Ministry of Health, Labour and Welfare's Fourth Cancer Control Basic Plan provides the strategic framework for radiotherapy infrastructure, promoting both equalisation (geographic accessibility) and concentration (operational efficiency) of high-cost medical equipment, including radiotherapy devices .• The Cancer Control Promotion Council, as part of the Cancer Control Basic Plan implementation, monitors IMRT availability at designated cancer care hospitals. Data indicates that while the proportion of hospitals offering IMRT has increased by 5.9 percentage points, approximately 20% still lack this capability, requiring ongoing improvement .• The Ministry of Health's demand projections for 2040 indicate that radiotherapy demand will increase by 38% relative to 2025 levels, compared to an 11% decline in surgical procedures, informing infrastructure planning and investment priorities .• The Japan Agency for Medical Research and Development is conducting research evaluating MR-Linac efficacy and safety, with findings expected to inform the establishment of appropriate provision systems for advanced radiotherapy .• The government supports research on hypofractionated radiotherapy shorter treatment courses to reduce patient transport burden and contribute to sustainability objectives, with plans to implement effective and safe treatments upon evidence validation .• The Radiation Therapy-Related Personnel Training and Workforce Development initiative addresses the shortage of specialised radiotherapy nurses and other personnel, with the Ministry of Health collaborating with professional organisations to expand training .• The Medical Care Act regulates medical device safety and quality, with the Pharmaceuticals and Medical Devices Agency providing oversight for radiotherapy equipment including LINACs, Gamma Knife, and proton therapy systems.Segment AnalysisJapan Radiotherapy Market By Therapy Type• External Beam Radiotherapy (EBRT): This is the largest therapy segment, supported by an installed base of 936 linear accelerators documented in the Japanese Society for Radiation Oncology's 2015 structure survey .

The LINAC fleet includes 754 dual-energy units, 867 units with 3D conformal radiotherapy functions, and 628 units with IMRT capability . The segment is driven by the clinical dominance of IMRT, VMAT, and IGRT techniques. The OXRAY system, launched in July 2023, represents the latest advancement in domestic EBRT technology, featuring O-ring gantry, dual kV imaging, and motion-tracking irradiation .• Internal / Brachytherapy: This segment remains clinically established, with the 2015 structure survey documenting 129 192Ir remote afterloading systems and 43 Gamma Knife units . Brachytherapy is particularly important for prostate, gynaecological, and breast cancers. The segment benefits from domestic manufacturing capability, with Sumitomo Heavy Industries supplying medical accelerator components and systems .• Systemic Radiotherapy: This is the fastest-growing therapy segment, driven by the emergence of novel radiopharmaceuticals and targeted radionuclide therapies. The Ministry of Health's "Basic Policy 2025" for Economic and Fiscal Management explicitly identifies the promotion of nuclear medicine therapy and the establishment of infrastructure to enable high-quality medical care using medical radioisotopes .

Sumitomo Heavy Industries has supplied more than 250 PET cyclotron systems worldwide and is developing radiopharmacy solutions .Japan Radiotherapy Market By Offering• Radiotherapy Systems/Equipment: This segment holds the largest market share by revenue, driven by high capital costs and sustained government investment. Major equipment suppliers include Varian Medical Systems, Elekta, and Accuray , alongside domestic manufacturers including Hitachi High-Tech and Sumitomo Heavy Industries. Hitachi High-Tech launched OXRAY in July 2023, a domestically produced image-guided X-ray therapy system . Sumitomo Heavy Industries supplies proton therapy systems based on cyclotron technology, with delivery of its first system to the National Cancer Center Hospital East in 1997 .• Software & Services: This is the fastest-growing segment, reflecting the increasing digitalisation of radiation oncology. The software component includes advanced treatment planning systems the OXRAY system supports adaptive radiotherapy, expected to become mainstream . The services component encompasses installation, comprehensive maintenance, clinical training, and technical support.

The Japanese market benefits from strong domestic service capabilities due to local manufacturing presence.Japan Radiotherapy Market By Application• Breast Cancer: This is a major application segment, with breast cancer ranking among the most frequent malignancies in Japan. Radiotherapy plays a central role in breast-conserving therapy and post-mastectomy treatment. Hypofractionation protocols are increasingly adopted to optimise treatment efficiency.• Prostate Cancer: A significant application area, with widespread use of EBRT and brachytherapy. Proton therapy, including domestic systems from Sumitomo Heavy Industries, is deployed for prostate cancer . The OXRAY system's motion-tracking irradiation is particularly beneficial for prostate cancer .• Lung Cancer: This segment is growing, with increased adoption of SBRT and motion-tracking techniques. The OXRAY system's real-time tumour tracking is specifically indicated for lung cancer treatment .• Head & Neck Cancer: This is a critical application due to anatomical complexity, requiring highly conformal radiation delivery.

IMRT is the standard of care, with approximately 20% of cancer hospitals still requiring IMRT capability .• Central Nervous System / Brain: This is a significant application, with Gamma Knife (43 units documented in 2015) and stereotactic radiosurgery for brain metastases . Proton therapy is deployed for paediatric brain tumours.• Gastro-intestinal: Applications include oesophageal, rectal, liver, and pancreatic cancers. The OXRAY system enables treatment of complex-shaped tumours .• Other Applications: Includes paediatric cancers a priority for proton therapy as well as gynaecological, haematological, and palliative care indications.Japan Radiotherapy Market By End User• Hospitals & Integrated Cancer Centres: This is the largest end-user segment, operating within the public health system. Designated cancer care hospitals, including national cancer centres and university hospitals, manage the most complex equipment fleets. The National Cancer Center Hospital East received Sumitomo Heavy Industries' first proton therapy system in 1997 . These institutions are the primary beneficiaries of government investment programmes.• Standalone Radiotherapy Centres: This segment includes specialised centres and private facilities.

Gamma Knife and Cyberknife specialty centres operate alongside comprehensive cancer centres . The segment is growing as outpatient care expands.• Academic/Research Institutions: This is the fastest-growing segment, reflecting their central role in advancing the field. Kyoto University partnered with Hitachi High-Tech to develop OXRAY . The National Cancer Center and university hospitals lead clinical trials and technology validation.• Other Healthcare Facilities: Includes regional hospitals and community facilities. The government's equalisation policy aims to improve access in underserved regions while maintaining quality through concentration of high-cost equipment .Japan Radiotherapy Market Economics• Equipment procurement in Japan is conducted through public and private hospital budgets, with government subsidies for designated cancer centres. The Ministry of Health's equalisation and concentration policy influences procurement decisions, balancing access with operational efficiency .• The economic value of radiotherapy is well-recognised, with hypofractionation reducing patient transport burden and contributing to sustainability.

The government is promoting research on shorter treatment courses to reduce the number of hospital visits .• Domestic manufacturing is expected to reduce equipment and maintenance costs. The OXRAY system, developed domestically, eliminates language and cultural barriers in problem resolution and software improvement, reducing support costs and improving responsiveness .• Equipment downtime directly affects patient access and treatment outcomes. With LINACs operating at high capacity the 2015 survey documented 936 units treating patients across 47 prefectures effective maintenance is critical .• Workforce economics present a challenge. The shortage of specialised radiotherapy nurses and other personnel increases reliance on service providers and automated solutions .• The cost of cybersecurity and software modernisation is an emerging factor, with connected radiotherapy devices requiring ongoing patch management. The OXRAY system's software-driven capabilities highlight the importance of cybersecurity in modern radiotherapy .Market Outlook by Infrastructure, Investment and Industry Development• The Ministry of Health, Labour and Welfare's Fourth Cancer Control Basic Plan continues through the 2020s, with the government actively promoting both equalisation and concentration of high-cost radiotherapy equipment . Demand for radiotherapy is projected to increase by 38% between 2025 and 2040 .• Domestic manufacturing is achieving major milestones.

Hitachi High-Tech launched OXRAY in July 2023, a domestically produced image-guided X-ray therapy system developed in partnership with Kyoto University . The system features O-ring gantry, dual kV imaging, cone-beam CT, and motion-tracking irradiation, supporting adaptive radiotherapy .• Sumitomo Heavy Industries continues to develop proton therapy and BNCT systems, with more than 50 years of accelerator manufacturing experience and over 250 PET cyclotron systems supplied worldwide .• The Japanese government is evaluating MR-Linac through AMED research, with findings expected to inform the establishment of appropriate provision systems for advanced radiotherapy . The research addresses both efficacy and safety, with the government committed to ensuring patients who need advanced radiotherapy can access it appropriately.• Workforce development is a critical priority. The Ministry of Health is collaborating with professional organisations to expand training of specialised radiotherapy nurses and address the shortage of radiation oncologists and medical physicists . The decline in the proportion of cancer hospitals with dedicated radiotherapy nurses below 50% underscores the urgency of these efforts.• Infrastructure expansion continues, with the government supporting the development of radiotherapy provision systems across Japan's 47 prefectures. However, approximately 20% of cancer care hospitals still lack IMRT capability, indicating ongoing investment requirements .• Digital transformation is enabling adaptive radiotherapy, expected to become mainstream .

The OXRAY system's support for adaptive radiotherapy positions Japanese technology at the forefront of this trend. The government's hypofractionation research aims to reduce patient visits while maintaining clinical efficacy .• The long-term outlook remains positive as cancer incidence rises, the population ages, and sustained government policy commitment drives infrastructure and technology investment. The projected 38% increase in radiotherapy demand through 2040 ensures continued market growth, supported by domestic manufacturing innovation and workforce development initiatives .Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Radiotherapy Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Therapy Type• External Beam Radiotherapy (EBRT)• Internal / Brachytherapy• Systemic RadiotherapyBy Offering• Radiotherapy Systems/Equipment• Software & ServicesBy Application• Breast Cancer• Prostate Cancer• Lung Cancer• Head & Neck Cancer• Central Nervous System / Brain• Gastro-intestinal• Other ApplicationsBy End User• Hospitals & Integrated Cancer Centers• Standalone Radiotherapy Centers• Academic/Research Institutions• Other Healthcare Facilities.